275 related articles for article (PubMed ID: 27262212)
1. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
[TBL] [Abstract][Full Text] [Related]
2. Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
Zhang Y; Wang W; Wang Y; Xu Y; Tian Y; Huang M; Lu Y
J Thorac Oncol; 2016 May; 11(5):e59-e62. PubMed ID: 26724472
[TBL] [Abstract][Full Text] [Related]
3. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
[TBL] [Abstract][Full Text] [Related]
4. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract][Full Text] [Related]
5. MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.
Yin W; Cheng J; Tang Z; Toruner G; Hu S; Guo M; Robinson M; Medeiros LJ; Tang G
Clin Lung Cancer; 2021 Jul; 22(4):e512-e518. PubMed ID: 33288441
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
[TBL] [Abstract][Full Text] [Related]
7. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
8. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
9. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
[TBL] [Abstract][Full Text] [Related]
10. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E
Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients.
Seo AN; Park KU; Choe G; Kim WH; Kim DW; Kang SB; Lee HS
Tumour Biol; 2015 Dec; 36(12):9813-21. PubMed ID: 26159851
[TBL] [Abstract][Full Text] [Related]
12. Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.
Duncan DJ; Vandenberghe ME; Scott MLJ; Barker C
PLoS One; 2019; 14(10):e0223926. PubMed ID: 31613934
[TBL] [Abstract][Full Text] [Related]
13. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
16. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
[TBL] [Abstract][Full Text] [Related]
17. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Schildhaus HU; Schultheis AM; Rüschoff J; Binot E; Merkelbach-Bruse S; Fassunke J; Schulte W; Ko YD; Schlesinger A; Bos M; Gardizi M; Engel-Riedel W; Brockmann M; Serke M; Gerigk U; Hekmat K; Frank KF; Reiser M; Schulz H; Krüger S; Stoelben E; Zander T; Wolf J; Buettner R
Clin Cancer Res; 2015 Feb; 21(4):907-15. PubMed ID: 25492085
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
[TBL] [Abstract][Full Text] [Related]
19. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Sunami K; Furuta K; Tsuta K; Sasada S; Izumo T; Nakaoku T; Shimada Y; Saito M; Nokihara H; Watanabe S; Ohe Y; Kohno T
J Thorac Oncol; 2016 Feb; 11(2):203-12. PubMed ID: 26845116
[TBL] [Abstract][Full Text] [Related]
20. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]